Table 2.
The efficacy of combination of TACE with RFA or MWA vs. monotherapy.
| References | Methods | Patients | Age (years) | Size (cm) | Response rates (%) | Overall survival (OS) rates (%) | OS P value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| 0.5 yr | 1 yr | 1.5 yr | 2 yr | |||||||
| Liu et al. [44] | TACE | 43 | 44-78 | 5-14 | 67.4 | — | — | — | — | 0.081 |
| TACE-RFA | 45 | 45-75 | 4-15 | 91.1 | — | — | — | — | ||
|
| ||||||||||
| Peng et al. [46] | RFA | 95 | 55.3 ± 13.3 | 3.39 ± 1.35 | 96.8 | — | 66.6 | — | — | 0.002 |
| TACE-RFA | 94 | 53.3 ± 11.0 | 3.47 ± 1.44 | 96.8 | — | 92.6 | — | — | ||
|
| ||||||||||
| Liu et al. [50] | TACE | 18 | 51.9 ± 13.6 | 6.7 ± 1.5 | 38.9 | 50 | 11.1 | 0 | 0 | 0.003 |
| TACE-MWA | 16 | 52.1 ± 14.5 | 6.8 ± 1.5 | 87.5 | 75 | 33.3 | 18.7 | 6.25 | ||
|
| ||||||||||
| Chen et al. [51] | TACE | 96 | 59.7 ± 10.5 | 2.88 ± 1.25 | 46.3 | 96.9 | 87.2 | 81.1 | 77 | 0.317 |
| TACE-MWA | 48 | 58.8 ± 9.6 | 2.74 ± 1.09 | 92.1 | 100 | 91.7 | 88.5 | 88.5 | ||
|
| ||||||||||
| Zheng et al. [52] | TACE | 166 | 54.6 ± 10.5 | 8.5 ± 2.5 | 55.4 | — | 59 | — | 40.4 | <0.001 |
| TACE-MWA | 92 | 53.3 ± 8.2 | 9.1 ± 2.8 | 81.5 | — | 85.9 | — | 59.8 | ||